Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib.
about
Homoharringtonine suppresses imatinib resistance via the Bcl-6/p53 pathway in chronic myeloid leukemia cell linesThe Safety of Bosutinib for the Treatment of Chronic Myeloid Leukemia.Second line small molecule therapy options for treating chronic myeloid leukemia.Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects.Bosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease.Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy.Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment.Practical Management of Toxicities Associated With Bosutinib in Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia.Treating the chronic-phase chronic myeloid leukemia patient: which TKI, when to switch and when to stop?Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects.Bosutinib in chronic myeloid leukemia: patient selection and perspectives.Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase 1/2 study.
P2860
Q33914049-E8BB3E6E-716C-4EE3-9740-8E282D449CC1Q38642952-6E4E7333-E38C-41A5-95DE-F9967CE48C5BQ38789049-19C0ECE0-2338-4C40-85DF-70D190FB42EDQ39310587-5C152057-6CC9-4CFB-B875-2063E9190493Q46220838-12565645-61EB-439E-817C-FB691BE613B1Q48124245-043F4AE7-E501-4F73-AC71-C1BCE20D72CDQ48275281-07CCF648-4E54-4A6F-9939-C9D07F543A5BQ49553324-CFEF70C2-BDED-4EF5-9B7D-A6965212F7C4Q50997822-9665E2CC-7A17-4FE6-A37E-3AC2D77EAFDAQ51415497-0A2A3682-BA95-415E-97C1-EB8A6032C488Q52562694-753865C5-2DEC-4291-AA6D-DA2817DAA39DQ52816089-E2C693D4-E937-4179-9AD1-1B8F6882C573Q54109036-BEA16D44-59BB-4FC8-9CCA-E429622BBB91
P2860
Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Factors influencing long-term ...... ant or intolerant to imatinib.
@ast
Factors influencing long-term ...... ant or intolerant to imatinib.
@en
type
label
Factors influencing long-term ...... ant or intolerant to imatinib.
@ast
Factors influencing long-term ...... ant or intolerant to imatinib.
@en
prefLabel
Factors influencing long-term ...... ant or intolerant to imatinib.
@ast
Factors influencing long-term ...... ant or intolerant to imatinib.
@en
P2093
P2860
P50
P356
P1476
Factors influencing long-term ...... ant or intolerant to imatinib.
@en
P2093
Dong-Wook Kim
Hanna J Khoury
Jeff H Lipton
Kathleen Turnbull
Mark Shapiro
Maureen G Conlan
Philippe Schafhausen
Tim H Brümmendorf
P2860
P304
P356
10.1111/BJH.13801
P407
P577
2015-11-04T00:00:00Z